One approved HNSCC therapy (cetuximab, an FDA approved drug for the treatment of HNSCC) and various investigational therapies (e.g., use of small molecule inhibitors, such as erlotinib) target EGFR. This evidence concerns the gene EGFR and head and neck squamous cell carcinoma.